

LIGAND PHARMACEUTICALS INC
Form SC 13G/A
February 11, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

**Under the Securities Exchange Act of 1934
(Amendment No. 2)***

LIGAND PHARMACEUTICALS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

53220K207

(CUSIP Number)

December 31, 2009

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 53220K207

NAMES OF REPORTING PERSONS

- 1** UBS AG (for the benefit and on behalf of UBS Investment Bank, Wealth Management USA, and Global Wealth Management and Business Banking business groups of UBS AG (See Item 7))

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

- 2**
 (a) ☐
 (b) ☐

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

- 4**
 Switzerland

SOLE VOTING POWER

5

NUMBER OF 5,770,524

SHARED VOTING POWER

6

SHARES
 BENEFICIALLY
 OWNED BY 0

SOLE DISPOSITIVE POWER

7

EACH
 REPORTING
 PERSON 5,770,524

SHARED DISPOSITIVE POWER

8

WITH:
 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

5,770,524

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.11%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

BK

CUSIP No. 53220K207

Item 1(a) Name of Issuer

LIGAND PHARMACEUTICALS INC

Item 1(b) Address of Issuer's Principal Executive Offices:

10275 Science Center Drive

San Diego, California 92121-1117

Item 2(a) Name of Person Filing:

UBS AG

Item 2(b) Address of Principal Business Office:

UBS AG's principal business office is:

Bahnhofstrasse 45

PO Box CH-8021

Zurich, Switzerland

Item 2(c) Citizenship:

Switzerland

Item 2(d) Title of Class of Securities

Common Stock

Item 2(e) CUSIP Number:

53220K207

Item 3. Type of Person Filing:

UBS AG is classified as a Bank as defined in section 3(a)(6) of the Act pursuant to no-action relief granted by the staff of the Securities and Exchange Commission.

CUSIP No. 53220K207

Item 4 (a)-(c)(iv). Ownership:

Items 5-11 of the cover pages are incorporated by reference.

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on By the Parent Holding Company:

This statement on Schedule 13G is being filed by UBS AG on behalf of itself and the subsidiaries listed below. The securities being reported on by UBS AG were acquired directly by UBS AG directly and certain of such subsidiaries.

UBS AG London Branch

UBS Portfolio LLC

UBS Ltd

UBS Warburg Private Clients Ltd

UBS AG Tokyo Branch

UBS AG (Switzerland)

UBS Warburg Securities (Pty) Ltd (South Africa)

UBS International Ltd

UBS Warburg Securities Ltd

UBS Warburg Corretora de Cambio e Valores

Mobiliarios S.A.

UBS Warburg Trading S.A.

UBS Bank S.A.

UBS Bunting Warburg Inc

UBS Capital LLC

UBS AG Brazil

UBS Limited

UBS Capital Asia Pacific Ltd

CUSIP No. 53220K207

UBS Capital Holdings LLC

UBS Capital Jersey Ltd

UBS Capital BV

UBS Warburg AG (Frankfurt)

UBS Securities Australia Ltd

UBS Securities Canada Inc.

UBS Securities Hong Kong Ltd

UBS Securities (Japan) Ltd

UBS Securities LLC

UBS Securities New Zealand Limited

UBS New Zealand Limited

UBS AG Australia Branch

UBS Capital Markets LP

UBS Capital Latin America LDC

UBS Securities France SA

UBS AG Canada Branch

PaineWebber Capital Inc

Paine Webber International Inc

UBS Financial Services Incorporated of Puerto Rico

UBS Americas Inc

UBS Financial Services Inc.

UBS (Bahamas) LTD

UBS (Cayman Islands) LTD

UBS (France) SA

UBS (Italia) SpA

UBS (Luxemberg) SA

UBS (Luxemberg) SA Austria Branch

UBS (Monaco) S.A.

UBS AG Brazil

UBS AG New York (101 Park Avenue)

UBS AG Hong Kong Branch

UBS AG Jersey Branch

UBS AG Singapore Branch

UBS AG Stamford Branch

UBS Assessores LTD

UBS Bank (Canada)

UBS Belgium SA/NV

UBS Deutschland AG

UBS Espana S.A.

UBS Swiss Financial Advisors AG

UBS Wealth Management AG

UBS Wealth Management (UK) Ltd

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9 Notice of Dissolution of Group:

Not Applicable

Item 10. Certification:

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

By signing below, the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 53220K207

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

By: /s/ Anthony Defilippis
Anthony Defilippis
Executive Director

By: /s/ Gordon Kiesling
Gordon Kiesling
Executive Director

Date: February 11, 2010